Metformin is an oral antihyperglycemic biguanide used as adjunct therapy with diet and exercise in type 2 diabetes mellitus. It improves glycemic control in adults and selected pediatric populations. U.S. approval history for GLUCOPHAGE began in 1995.
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
New research reveals metformin regulates blood sugar through brain pathways involving the Rap1 protein in the hypothalamus. The study shows suppressing Rap1 in the brain prevents metformin from lowering blood sugar in diabetic mice. These findings could lead to new diabetes treatments targeting this brain pathway.
New NICE guidance recommends offering SGLT-2 inhibitors earlier in type 2 diabetes treatment, potentially preventing 17,000 deaths over three years while saving the NHS £560 million through generic medicines.
Eli Lilly announced positive Phase 3 results for EBGLYSS in pediatric atopic dermatitis, orforglipron in diabetes showing superiority over Rybelsus, and Retevmo in early-stage lung cancer, expanding potential indications across its portfolio.
Recent studies reveal metformin's varied effects: it may extend lifespan in older women with diabetes by 30 percent, but failed to improve long COVID symptoms when given after infection developed.
Eli Lilly's orforglipron demonstrated superior A1C reduction and weight loss compared to oral semaglutide in the ACHIEVE-3 trial, with regulatory submissions filed in over 40 countries and a potential US decision expected in Q2 2026.
Orforglipron, an oral GLP-1 receptor agonist, demonstrated greater reductions in HbA1c and body weight compared to oral semaglutide in adults with type 2 diabetes, with more patients achieving strict glycemic targets at one year.
New research reveals how GLP-1 receptor agonists promote pancreatic health through gene expression changes and interact bidirectionally with gut microbiome, while real-world users report unexpected lifestyle changes alongside weight loss.
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
NATCO Pharma has licensed its semaglutide generic formulation to Eris Lifesciences for the Indian market, with a launch expected in March 2026 following CDSCO approval. The partnership targets type 2 diabetes management as the molecule loses patent exclusivity in India.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07589387 |
Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3 |
NOT_YET_RECRUITING | NA |
| NCT07585396 |
Inositol in Letrozol Resistant PCOS Women |
COMPLETED | PHASE2/PHASE3 |
| NCT07570082 |
Drug-Drug Interaction Study of Atumelnant in Healthy Participants |
RECRUITING | PHASE1 |
| NCT07568574 |
Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes |
ENROLLING_BY_INVITATION | NA |
| NCT07567781 |
A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults. |
RECRUITING | PHASE1 |
| NCT07541456 |
Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes |
COMPLETED | PHASE4 |
| NCT07531108 |
Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes |
COMPLETED | PHASE4 |
| NCT07530289 |
A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018) |
RECRUITING | PHASE1 |
| NCT07520110 |
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis |
NOT_YET_RECRUITING | PHASE3 |
| NCT07502001 |
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin |
NOT_YET_RECRUITING | PHASE1 |
